SMART INNOVATIVE APPROACH FOR DESIGNING FLUVOXAMINE LOADED BIO-NANOSUSPENSION FOR THE MANAGEMENT OF DEPRESSION
Objective: Design and evaluation of fluvoxamine loaded bio-nanosuspensions using biopolymer which was isolated from the wood of Santalum album used as the stabilizer.
Methods: The main aim of the present investigation was to obtain an ocular drug delivery system with improved stability using biopolymer. The fluvoxamine loaded Bio-nanosuspension was prepared using novel biopolymer isolated from Santalum album by sonication solvent evaporation method with different ratios (1%, 2%, 3%, 4% and 5%) and evaluated for particle size, polydispersity index, zeta potential, pH stability studies, %entrapment efficacy, in vitro drug release, stability studies.
Results: The prepared bio-nanosuspension was subjected to the best formulation based on the comparison of above-mentioned evaluation parameters, so Fb3 (3%) formulation was found to be the best formulation showing an R2 value of 0.9744, T50% of 31.3 h and T80% of 50.1 h respectively. According to the release kinetics, the best fit model was found to be Peppas Korsmeyer with Fickian Diffusion (Higuchi Matrix) as the mechanism of drug release. Santalum album provided excellent stability for the formulation, and resulting particle size for the best formulation was found to be 196 nm. The bio-nanosuspension had Polydispersity Index (PDI) of 0.19 with zeta potential of-20mV.
Conclusion: The prepared bio-nanosuspension was found to be safe and compatible with the ophthalmic delivery for treatment of depression.
2. Muller. Nanosuspensions as particulate drug formulation in therapy rationale for development and what we can expect for the future. Adv Drug Delivery Rev 2001;47:3-19.
3. Liversidge. Surface modified drug nanoparticles, US Patent No. 5; 1992. p. 145-684.
4. Sucker H, Muller RH, Hildebrand GE. Eds. Pharmaceutical Technology: Modern Dosage forms. WVG MBH, Stuttgart; 1998. p. 383-91.
5. Moschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 2004;58:615-9.
6. Francis D. Ion milling coupled field emission scanning electron microscopy reveals a current misunderstanding of the morphology of polymeric nanoparticles. Eur J Pharm Biopharm 2015;89:56-61.
7. Dong C. Synthesis of magnetic chitosan nanoparticle and its adsorption property for humic acid from aqueous solution. Colloids Surf A 2014;446:179-89.
8. Qingguo Xu. Nanotechnology approaches for ocular drug delivery, Middle East. Afr J Ophthalmol 2013;20:26-37.
9. Muller RH, Bohm BHL. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. medpharm scientific publishers, Stuttgart; 1998. p. 149-74.
10. Muller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution, US Patent No. 5; 1999. p. 858, 410.
11. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004;113:151-70.
12. Bisrat M, Nystrom C. Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int J Pharm 1988;47:223-31.
13. Mosharraf M, Nystrom C. The effect of particle size shape on the surface specific dissolution rate of micronized practically insoluble drugs. Int J Pharm 1995;122:35-47.
14. Zhang J. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm 2006;323:153-63.
15. Duchne D, Ponchel G. Bioadhesion of solid oral dosage forms, why and how? Eur J Pharm Biopharm 1997;47:15-23.
16. Yoncheva K, Lizarraga E, Irache JM. Pegylated nanoparticles based on poly (methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. Eur J Pharm Sci 2005;24:411-9.
17. Hui HW, Robinson JR. Effect of particle dissolution rate on ocular drug bioavailability. J Pharm Sci 1986;75:280-7.
18. Schoenwald RD, Stewart P. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J Pharm Sci 1980;69:391-4.
19. Novir SB. Computational investigation of structural and electronic properties of cis and trans structures of fluvoxamine as a nano-drug. Int J Comput Theor Chem 2017;1105:33-45.
20. Dawood NM. Formulation and characterization of lafutidine nanosuspension for oral drug delivery system. Int J Appl Pharm 2018;10:20-30.
21. Kilor V. Development of stable nanosuspension loaded oral films of glimepiride with improved bioavailability. Int J Appl Pharm 2017;9:28-33.